Hikma Pharmaceuticals (HKMPF)
(Delayed Data from OTC)
$25.16 USD
0.00 (0.00%)
Updated Oct 3, 2024 02:53 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
HKMPF 25.16 0.00(0.00%)
Will HKMPF be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for HKMPF based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for HKMPF
Hikma Pharmaceuticals (HKMPF) Upgraded to Buy: Here's What You Should Know
HKMPF: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for HKMPF
Hikma Pharmaceuticals just upgraded at Berenberg, here's why
Jazz And Hikma Accused Of Delaying Sleep Disorder Generic Drug To Maintain High Prices
Hikma price target raised to 2,100 GBp from 2,000 GBp at Berenberg
Hikma Pharmaceuticals PLC (HKMPF) Q2 2024 Earnings Call Transcript
Hikma Pharmaceuticals PLC (HKMPF) Q2 2024 Pre-Recorded Presentation Transcript